Nucleo.

Nucleo

Nucleo is an AI-powered platform that automates CT scan analysis for oncology care, delivering faster and more consistent cancer diagnostics than manual methods. Backed by Y Combinator and trusted by leading hospitals worldwide, Nucleo helps clinicians make critical decisions with greater speed and accuracy.

Product Highlights

• Automated CT Segmentation: Analyzes scans in a fraction of the time required for manual segmentation
• High Expert Agreement: Achieves near-perfect alignment with expert radiologist assessments
• RECIST-Compliant Measurements: Delivers precise tumor lesion sizing according to standardized oncology criteria
• Body Composition Analysis: Automatically quantifies fat and muscle mass to assess sarcopenia
• Target Lesion Classification: Distinguishes between target and non-target lesions using AI-driven criteria

Use Cases

• Oncology Workflow Acceleration: Reduces diagnostic bottlenecks by automating time-consuming CT analysis tasks
• Treatment Monitoring: Enables consistent tracking of tumor progression and response to therapy over time
• Sarcopenia Screening: Supports early detection of muscle wasting to inform treatment planning and patient prognosis
• Clinical Trial Support: Standardizes lesion measurements to ensure reproducibility in research settings

Target Audience

Nucleo is designed for oncologists, radiologists, and healthcare institutions seeking to enhance diagnostic efficiency without compromising accuracy. It serves hospitals and cancer centers that handle high volumes of CT imaging and require reliable, scalable solutions for patient care.